• Explore /
  • Poster
  • / Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates.

Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates.

Abstract Video & Slides Poster

Authors

null

Jennifer O'Neil

Xilio Therapeutics, Waltham, MA

Jennifer O'Neil , Wilson Guzman , Oleg Yerov , Parker Johnson , Manoussa Fanny , Justin Greene , Megan McLaughlin , Kurt Jenkins , Rebekah O'Donnell , Huawei Qiu , Benjamin Nicholson , William Avery , Ronan C. O'Hagan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2563)

DOI

10.1200/JCO.2021.39.15_suppl.2563

Abstract #

2563

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Stephanie A. Berg

First Author: Ahmad A. Tarhini

First Author: Yu Chen

First Author: Shannon Neville Westin